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ABSTRACT 
Many countries are incorporating direct patient reporting of adverse drug reactions (ADRs) into their pharmacovigilance systems as 
patients provide a different insight into drug safety compared to healthcare professionals. In Malaysia, consumer reporting of ADRs 
and issues with product qualitiesbegan in 2007.The aim of this study was to examine consumer reports in terms of ADR 
categoriesby System Organ Class (SOC), suspected products and the seriousness of the ADRs. 
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The Malaysian Pharmacovigilance database was 
retrospectively searched from 2008 to 2015 to identify 
consumer reports. We excluded reports of adverse 
events following immunisation, and descriptively 
analysed eligible reports using SPSS version 20. Chi-
squared test with significance level ofp < 0.05 was used 
to evaluate the association of various categorical 
variables with serious ADRs. 
FINDINGS: 
Out of the 101,957 ADR reports available in the 
National ADR database for the period 2008 to 2015, 
only 81 (0.08%) reports were by consumers. The 
majority (64%) of the consumer reports used the 
consumer reporting form while a small proportion used 
ADRs form designed for healthcare professionals. 
Almost half of these 81 reports involved 
complementary and alternative medicines (CAM)while 
other major classes of products involved were 
prescription medicines (19%) and cosmetics (11%). Of 
the total ADRs reports, the three main SOC involved 
were skin and appendages disorders (26%), body as a 
whole (25%), and central and peripheral nervous 
system disorders (9%). The Malaysian 
Pharmacovigilance Centre obtained and tested 
45samples, of which 19(42%) were CAMs products 
found to be adulterated with prescription drugs while 4 
cosmetic productsexceeded the permitted limit for 
hydroquinone or mercury. More than half of the reports 
involved unregistered products or unapproved 
cosmetics. Two factors found to be significantly 
associated with serious ADRs were status of product 
registration and presence of product adulteration. 
CONCLUSION: 
Our preliminary findings show that consumers have the 
potential to provide valuable feedbackparticularly for 
serious ADR reports. The National Centre should 
allocate specific resources for the assessment of 
consumer reports to strengthen pharmacovigilance.
 
 
